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Abstract: Background:  Precision medicine approaches targeting patients 
based on disease subtype have transformed approaches to cancer, asthma, 
and other heterogeneous syndromes.  Two distinct subphenotypes of ARDS 
have been identified in three US-based clinical trials and respond 
differently to positive end-expiratory pressure and fluid management.  It 
remains unknown if these subphenotypes exist in different populations and 
respond differently to pharmacotherapies. 
 
Methods:  We conducted a secondary analysis using data from 539 patients 
enrolled in a UK multicenter, placebo-controlled randomized trial of 
simvastatin for ARDS (HARP-2).  Latent class analysis was applied to 
baseline data without consideration of outcomes to identify 
subphenotypes.  Clinical outcomes were compared across subphenotypes and 
treatment groups.  
 
Findings:  A two class (two-subphenotype) model was an improvement over a 
one class model (p<0.0001), with 65% of subjects in the hypo-inflammatory 
subphenotype and 35% in the hyper-inflammatory subphenotype.  Additional 
classes did not improve model fit.  The clinical and biological 
characteristics of the two subphenotypes were similar to prior studies.  
While the original trial found no difference in 28-day survival between 
placebo and simvastatin, significantly different survival was identified 
across patients stratified by treatment and subphenotype (p<0.0001).  
Specifically, within the hyper-inflammatory subphenotype, patients 
treated with simvastatin had significantly higher 28-day survival 
compared to placebo (p = 0.008).  A similar pattern was observed for 90-
day survival. 
 
Interpretation:  Two subphenotypes of ARDS were identified in the HARP-2 
cohort, with distinct clinical and biological features and disparate 
clinical outcomes; the hyper-inflammatory subphenotype had improved 
survival with simvastatin compared to placebo.  These findings support 
further pursuit of predictive enrichment strategies in critical care 
clinical trials. 
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    April 12, 2018 
 
Dear Colleagues, 
 
We thank the editors and reviewers for their insightful and constructive comments on 
our manuscript ID THELANCET RM-D-18-00186R1, formerly entitled “Improved 
Survival in Hyper-inflammatory ARDS With Randomly Assigned Simvastatin.”   We 
have revised the manuscript, submitted a marked-up copy and provide below a point-
by-point response to the comments.   
 
Editorial Comments: 
 
C1:  We require TWO author signatures from every authors listed. All authors need to 
sign this form:  http://download.thelancet.com/flatcontentassets/authors/tlrm-author-
signatures.pdf AND each author must additionally complete and return this form: 
 http://download.thelancet.com/flatcontentassets/authors/icmje-coi-form.pdf. You can 
return these by email if it is easier.  
R1.  These forms have been completed and will be returned via email at the time of this 
revision. 
 
C2.  Please add a conflict of interest statement to the end of your paper, as per Lancet 
style. These statements should exactly match those given on your signed conflict of 
interest forms. If there are none then please state "The authors declared no conflicts of 
interest" or "The other authors declared no conflicts of interest." 
R2.  Done. 
 
C3.  Please add an Author contributions section to the end of your paper before the 
references, as per Lancet style. These statements should exactly match those given on 
your signed forms. Authors should be referred to by their initials in this section. 
R3.  Done. 
 
C4.  Please supply figures as high-resolution EPS format, exported directly from your 
statistical package if possible, rather than embedded in a Word file. (TIF for 
photographs). Formatting guidelines can be found 
at http://download.thelancet.com/flatcontentassets/authors/artwork-guidelines.pdf. 
Please ensure you have the necessary permissions required for any previously 
published artwork. 
R4.  Done. 
 
C5. Please check with your co-authors, and confirm, that all names are spelt correctly, 
and affiliations listed correctly. Please give full first names for all authors and supply 
(after author names on the title page) one preferred degree per author and indicate in 
the authorship if any authors are full professors. Please note that we can only have one 
corresponding author. 
R5.  Done. 
 
C6. Titles should be non-declamatory (ie, not state the findings of the paper) and 
should have a descriptor—ie, randomised trial, case-control study, prospective 
analysis, population-based study etc. Please suggest a new title. 
R6.  We suggest the following:  ARDS Subphenotypes and Differential Response to 
Simvastatin:  Secondary Analysis of a Randomized Controlled Trial. 
 
*Reply to Reviewers Comments
C7.  Please ensure your paper conforms to Lancet statistical reporting guidelines. 
Specifically, please give actual numbers (numerator and denominator) together with 
percentages;  do not translate HRs/RRs/ORs into percentages; provide p values to two 
significant figures, unless p<0.0001 ; KM plots should include number at risk in each 
group . 
R7.  Done. 
 
C8. Please ensure that main outcome measures include a result for each group plus a 
point estimate (eg, RR, HR) with a measure of precision (95% CI) for the difference 
between groups. 
R8.  We have provided the requested information for all outcome measures where 
feasible throughout the manuscript. 
 
Reviewer #6:  
C9.  The authors state 'Logistic regression was used for mortality, not for ventilator-
free days.' - Why was logistic regression used for a time to event outcome such as 
mortality? Were any patients were lost to follow up in the 28-day period? It seems 
inconsistent that the authors use the KM curve for displaying survival but then uses a 
modeling technique (logistic regression) that doesn't correspond to that.  
R9.  We apologize if this section of the manuscript remained confusing.  For the 
dichotomous outcome of mortality (p.9, second full paragraph, beginning “Mortality at 
28 days…), we used chi-square in unadjusted models and logistic regression for 
analyses of treatment interaction.  For the survival analysis, we compared time-to-event 
Kaplan-Meier curves using the log-rank test.  We have reworded this section of the 
statistical methods section (pp. 6-7) in an attempt to further clarify.  The number at risk 
for the survival analyses are denoted below the figures in Figures 2A and 2B.  
 
C10. The authors use models like zero-inflated Poisson regression. It would help to 
have the model diagnostics of all the models in the supplement as well as a line in the 
statistical analysis section stating that they checked the model diagnostics and if they 
were satisfactory.  
R10.  We appreciate this suggestion and the opportunity to expand on our statistical 
procedures.  We have added a statement to the statistical methods confirming our use 
of model diagnostics, as suggested by the reviewer, as well as additional details on the 
model checking procedures in the supplementary methods.  Dr. Delucchi, the second 
author on this paper, is a senior biostatistician at UCSF with extensive experience in 
these models and related model diagnostics. 
 
C11.  R35: I find the authors response regarding adjustment of the covariates and their 
comparison of results of this paper to the results from their original RCT worrisome. 
The authors say that 'randomization was well balanced within the phenotypes, 
indicating that imbalanced randomization within phenotype is unlikely to be driving 
our findings.'. It needs to be understood that the LCA is a statistical technique which 
estimates with a certain probability which class each patient falls in. At the end of the 
day, it's an estimate and associated with it there is variability and this cannot be 
compared to groups that are assigned through randomization. Tweaking parameters of 
the LCA could lead to slightly different results with a different distribution in groups. 
Even in observational studies, baseline characteristics could be balanced between 
groups just due to chance. Studies like those would not be directly compared to a gold 
standard RCT. I would hence encourage the authors to soften their language in the 
paper regarding their comparison of results and avoid using univariate pvalues to 
make conclusions on whether the groups were balanced like in an RCT. Table 1 is also 
very enlightening. If I were to use the same argument as the authors did regarding 
balance of the groups using Table 1, I could say that age and Direct ARDS risk factors 
are significantly different in both the phenotype groups, then this provides all the more 
reason why they should be adjusted for as confounders when evaluating if those groups 
are associated with outcomes such as mortality.  
R11.  We appreciate the chance to expand further on this issue.  When we cited Table 1 
as an example of randomization being well-balanced between the subphenotypes, we 
did not mean that the key clinical or biological characteristics were similar between the 
two subphenotypes, but rather that the proportion of patients assigned to simvastatin 
was similar in the two subphenotypes.  Furthermore, since variables like age and direct 
ARDS risk factors were the variables used to define the two subphenotypes, it is not 
clear to us what the meaning of analyses adjusted for these variables would be.  We 
think the more important analysis to address the reviewer’s concern about potential 
confounders is whether randomization was balanced within each subphenotype – that 
is, within subphenotype 2 or 1, were there important differences in clinical or 
biological features between patients assigned to simvastatin and patients assigned to 
placebo?  If there were for instance a major imbalance in age between subphenotype 2 
patients assigned to placebo and subphenotype 2 patients assigned to simvastatin, this 
imbalance could theoretically contribute to observed differences in survival between 
placebo and simvastatin patients in subphenotype 2.  However, as commented on in 
R29 on the prior revision, randomization was well-balanced within each subphenotype, 
so this should not be a concern.  Moreover, as previously noted, we have never 
adjusted for potential covariates in our previously published secondary analyses of 
randomized controlled trials.  We are not sure what covariates we would adjust for in 
the analyses of simvastatin vs placebo effect, since the simvastatin and placebo patients 
within the hyper-inflammatory subphenotype were otherwise similar.  However, we 
wish to be maximally responsive to the reviewer’s concern and as such have softened 
our language in the paper regarding comparison of results to the original randomized 
controlled trial.  Specifically, we have added two sentences to the Discussion that 
emphasize that it remains possible that unmeasured confounders could be contributing 
to these results and that a prospective randomized clinical trial to confirm these 
findings will be needed.  We hope these changes will address the reviewer’s concerns. 
 
C12.  In Table 1, the authors specify descriptive statistics for Gender. They do not 
specify if those values are for Males or Females. Please correct. 
R12.  We thank the reviewer for catching this omission.  We have corrected the 
language in the table.  
 
In conclusion, we wish to thank all the editors and reviewers for their time and for their 
thoughtful and constructive comments.  We think the manuscript has been greatly 
improved by their suggestions, and we look forward to the response to these revisions.   
 
 
Sincerely, 
 
Carolyn S. Calfee MD MAS 
On behalf of all authors 
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ABSTRACT: 
Background:  Precision medicine approaches targeting patients based on disease subtype 
have transformed approaches to cancer, asthma, and other heterogeneous syndromes.  Two 
distinct subphenotypes of ARDS have been identified in three US-based clinical trials and 
respond differently to positive end-expiratory pressure and fluid management.  It remains 
unknown if these subphenotypes exist in different populations and respond differently to 
pharmacotherapies. 
Methods:  We conducted a secondary analysis using data from 539 patients enrolled in a UK 
multicenter, placebo-controlled randomized trial of simvastatin for ARDS (HARP-2).  Latent 
class analysis was applied to baseline data without consideration of outcomes to identify 
subphenotypes.  Clinical outcomes were compared across subphenotypes and treatment 
groups.  
Findings:  A two class (two-subphenotype) model was an improvement over a one class model 
(p<0.0001), with 65% of subjects in the hypo-inflammatory subphenotype and 35% in the hyper-
inflammatory subphenotype.  Additional classes did not improve model fit.  The clinical and 
biological characteristics of the two subphenotypes were similar to prior studies.  While the 
original trial found no difference in 28-day survival between placebo and simvastatin, 
significantly different survival was identified across patients stratified by treatment and 
subphenotype (p<0.0001).  Specifically, within the hyper-inflammatory subphenotype, patients 
treated with simvastatin had significantly higher 28-day survival compared to placebo (p = 
0.008).  A similar pattern was observed for 90-day survival. 
Interpretation:  Two subphenotypes of ARDS were identified in the HARP-2 cohort, with 
distinct clinical and biological features and disparate clinical outcomes; the hyper-inflammatory 
subphenotype had improved survival with simvastatin compared to placebo.  These findings 
support further pursuit of predictive enrichment strategies in critical care clinical trials. 
Word count:   257/250  
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RESEARCH IN CONTEXT 
Evidence before this study:  Previous studies of ARDS patients, using data from U.S.-based 
randomized controlled trials, have identified two distinct subphenotypes with differential 
responses to mechanical ventilation and fluid therapy.  It is unknown whether these 
subphenotypes can be identified in different populations using different datasets and, more 
importantly, whether these subphenotypes respond differently to pharmacotherapies.  We 
searched PubMed on March 7, 2018 using the terms (ARDS or “acute lung injury”) AND 
(subtype OR subphenotype OR endotype) and no language restrictions and identified no prior 
studies reporting differential responses to pharmacotherapy by ARDS subphenotype. 
 
Added value of this study:  This study reports that two distinct ARDS subphenotypes were 
identified in a secondary analysis of a U.K.-based randomized controlled trial of simvastatin for 
ARDS.  Notably, the hyper-inflammatory subphenotype of ARDS had a survival benefit from 
simvastatin.  To our knowledge, this study is the first to report differential response to 
pharmacotherapy by molecular subphenotype in ARDS. 
 
Implications of all the available evidence:  While other areas of medicine (e.g. cancer, 
asthma) have made significant progress by identifying biologically distinct subtypes of disease 
with differential treatment responses, critical care medicine has lagged behind.  These findings 
suggest that targeting specific biological subtypes of critical illness syndromes in clinical trials 
may yield progress after decades of negative pharmacotherapy trials in the ICU. 
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INTRODUCTION 
 The acute respiratory distress syndrome (ARDS) is a common and frequently fatal cause 
of respiratory failure among critically ill patients, with an incidence of nearly 200,000 cases per 
year in the US alone, an estimated prevalence of 10% among critically ill patients worldwide, 
and mortality of 30-40%.1,2 ARDS is defined by clinical criteria including acute onset of 
hypoxemia (PaO2/FiO2 ratio < 300 mm Hg), bilateral chest radiographic opacities, and 
exclusion of cardiac failure as the sole cause of the syndrome.3  Since the first consensus 
definition of ARDS in 1988, experts have debated whether patients should be subdivided by 
natural history, clinical features, biology, or some combination thereof.4  During the ensuing 3 
decades, positive trials of several supportive care interventions, including most notably lung 
protective ventilation, have led to decreases in ARDS mortality – yet over the same time period, 
dozens of pharmacotherapies that seemed to show great promise in pre-clinical studies have 
failed in clinical trials.  One of the often-cited reasons for this discouraging failure rate has been 
the considerable clinical and biological heterogeneity within ARDS, but objective data have 
been lacking to guide a more precision approach to clinical trials. 
 Latent class analysis is a well-validated statistical method that uses objective criteria to 
identify subgroups within a broader population.  We previously applied latent class analysis in 
independent analyses of 3 cohorts of patients derived from NHLBI ARDS Network randomized 
controlled trials; in all 3 cohorts, summing to over 2000 patients, we observed strong evidence 
for two distinct and consistent subphenotypes of ARDS.5,6  In all 3 cohorts, one subphenotype 
representing roughly 30% of ARDS patients was consistently characterized by higher levels of 
inflammatory biomarkers, more profound shock and acidosis, and significantly worse clinical 
outcomes.  Of particular interest, we found that this hyper-inflammatory subphenotype had a 
significantly different response to randomly assigned positive end-expiratory pressure (PEEP) 
and fluid management strategy, compared to the hypo-inflammatory subphenotype.5,6  These 
findings have suggested that improved understanding of these subphenotypes may be critical to 
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future success in ARDS clinical trials.7  It remains unknown, however, whether these ARDS 
subphenotypes are generalizable to non-U.S. populations, whether they can be identified using 
less extensive datasets, and most importantly, whether they may respond differently to 
pharmacotherapies.   
 To test these questions, we designed a secondary analysis of a Phase 2B randomized 
controlled trial of simvastatin for ARDS, the Hydroxymethylglutaryl-CoA Reductase Inhibition 
with Simvastatin in Acute Lung Injury to Reduce Pulmonary Dysfunction-2 (HARP-2) Study.8  
Based on our prior research, we hypothesized a priori that latent class analysis of the HARP-2 
cohort would identify two distinct subphenotypes of ARDS with similar clinical and biological 
characteristics to those we have previously identified.  We also hypothesized, based on the anti-
inflammatory effects of statins in laboratory and pre-clinical models of ARDS,9 that patients with 
the hyper-inflammatory subphenotype would preferentially respond to simvastatin.   
 
METHODS 
Patient Sample 
HARP-2 was a multicenter randomized controlled trial conducted in the United Kingdom and 
Ireland comparing daily simvastatin 80 mg to placebo in 540 patients with ARDS.8  One patient 
withdrew consent for the use of their data, so 539 patients were analyzed.  Patients were 
enrolled within 48 hours of meeting ARDS criteria, and study drug was continued until Day 28, 
discharge from ICU, death, or development of a contraindication to continued statin therapy. 
The primary outcome of the study was ventilator-free days, with secondary outcomes of non-
pulmonary organ failure free days and mortality; there were no significant differences in any of 
these outcomes by treatment allocation.  
 
Assay Procedures 
 6 
Interleukin 6 (IL-6) and soluble tumor necrosis factor receptor-1 (sTNFr-1) were measured for 
this analysis using plasma drawn prior to randomization and stored at -80C. Biomarkers were 
measured in duplicate using commercially available enzyme-linked immunoassays (R&D 
Systems).  
 
Statistical Analysis 
To estimate the optimal number of classes in the data, latent class models were fit in Mplus v810 
using baseline demographics (age, gender), available baseline clinical data (direct and indirect 
ARDS risk factors, bilirubin, creatinine, platelet count, PaO2/FiO2 ratio, plateau pressure, tidal 
volume, use of vasopressors), and baseline IL-6 and sTNFr1 as class-defining variables 
(Supplemental Table 1).  Of note, fewer clinical and biomarker variables were available for 
these analyses than in our prior studies. Outcome variables were not included in the modeling.  
Models ranging from 1 to 4 classes were estimated to identify the optimal number of classes. 
From these four models, best-fit was evaluated using Bayesian Information Criteria (BIC), the 
Vuong-Lo-Mendell-Rubin likelihood ratio (VLMR) test (which compares fit of model k classes to 
k-1 classes), class size, and entropy.11,12  Prior to beginning this modeling, variables were 
examined for their distribution, and continuous variables with significantly skewed distributions 
were log-transformed.  To estimate model parameters, continuous variables were placed on a z-
scale with a mean of 0 and standard deviation of 1, as in our prior work.5,6 As a sensitivity 
analysis, we repeated these models including C-reactive protein (CRP) levels.  Additional 
details on the LCA modeling are in the supplementary appendix.  
 
Once the optimal number of classes was determined, study participants were assigned to their 
most likely class, and their baseline characteristics were compared using t-tests, Pearson’s chi-
square, or Wilcoxon rank sum test depending on the nature of the variable. Associations 
between class assignment and clinical outcomes were tested using chi-square for mortality (i.e., 
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the proportion who died) and Wilcoxon ranksum for ventilator-free days.  To test for interactions 
between treatment and class assignment, we used logistic regression for mortality and zero-
inflated Poisson regression for ventilator-free days.  Count-based models of ventilator-free-days 
were compared for best fit and tested for over-dispersion to inform model selection. Model 
diagnostics were satisfactory; details regarding model checking procedures are provided in the 
supplement.  To test for differential response to treatment by class for survival (time to death), 
we compared time-to-event Kaplan-Meier curves using the log-rank test. For modeling time to 
unassisted breathing, a competing risks model was estimated with death before Day 28 as the 
competing risk.13  Analyses other than LCA were carried out using SAS (Version 9.4, (SAS 
Institute, Cary, NC, USA).  Some results were previously reported in the form of an abstract.14 
 
Role of the Funding Source:  None 
 
Results  
Population Characteristics 
Baseline characteristics of patients enrolled in the HARP-2 trial are fully described in the 
original publication and are summarized in Supplemental Table 2.  Pneumonia was the most 
common contributing risk factor for ARDS (55%). Overall, median ventilator-free days were 13, 
and 28-day mortality was 24.5%.  
 
Two-class Model Optimally Fits the Population 
Analysis of the four LCA models showed that the 2-class model was a better fit for the 
population than a 1-class model, and additional classes did not improve model fit 
(Supplementary Table 3). Entropy in all models was 0.75 or greater, indicating adequate class 
separation. The Bayesian Information Criteria decreased as the number of classes in the model 
increased, indicating improved model fit with additional classes. The 2-class model had a 
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significantly improved fit compared to the one-class model (VLMR p < 0.0001); additional 
classes did not lead to significant improvement in model fit.  These findings, in conjunction with 
the relatively small number of patients in the additional class in a 3-class model (n = 40), led us 
to proceed using a 2-class model.  In the 2-class model, 353 (65%) patients were assigned to 
class 1 and 186 (35%) patients to class 2.  Of note, these proportions are consistent with our 
prior latent class analyses,5,6 despite the fact that the HARP-2 analyses used far fewer clinical 
and biomarker variables (n=14) as inputs than the prior work (n=35-37).  Inclusion of CRP levels 
in the LCA models as a sensitivity analysis did not meaningfully affect the results (data not 
shown). 
Average latent class probabilities were 0.93 for Class 1 and 0.92 for Class 2. These 
findings are also consistent with previous studies and indicative of robust class assignment.   
 
Comparison of Phenotypic Features and Outcomes Between Subphenotypes 
Class 2 had clinical and biological features similar to those found in prior studies and 
consistent with a hyper-inflammatory phenotype.  Specifically, as compared to Class 1, patients 
in Class 2 had higher values of sTNFr-1 and IL-6, lower platelet counts (Figure 1; Table 1), and 
more vasopressor use (Table 1; p < 0.001).   For simplicity, the classes will be referred to as the 
hypo-inflammatory subphenotype (Class 1) and the hyper-inflammatory subphenotype (Class 2) 
for the remainder of the manuscript.  Age and gender were similar across the subphenotypes.  
Although the distribution of direct and indirect ARDS risk factors was significantly different 
across the two subphenotypes (Table 1; p<0.0001), the most common ARDS risk factors of 
sepsis, pneumonia and aspiration were highly prevalent among both groups, as in prior studies. 
Also similar to prior studies, the hyper-inflammatory subphenotype patients had fewer ventilator-
free days (median 2 vs 18 days; p<0.0001), fewer non-pulmonary organ failure free days 
(median 15 vs 27 days; p<0.0001), and higher 28-day mortality (39% vs 17%, p<0.0001) 
compared to the hypo-inflammatory subphenotype (Table 2).  
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Survival Benefit Observed with Simvastatin in Hyper-inflammatory Subphenotype 
The original trial found no difference in 28-day survival curves between placebo and simvastatin 
(p=0.20).  In contrast, we observed significantly different survival curves across patients 
stratified by treatment and subphenotype (Figure 2A; p<0.0001).  Specifically, within the hyper-
inflammatory subphenotype, patients treated with simvastatin had significantly higher 28-day 
survival compared to patients treated with placebo (p = 0.008). This effect was not observed in 
the hypo-inflammatory subphenotype patients.  A similar pattern was observed for 90-day 
survival (Figure 2B; p<0.0001 for overall comparison; p=0.03 for hyper-inflammatory 
subphenotype simvastatin vs placebo).    
 
In contrast to the curves stratified by subphenotype and treatment, survival curves stratified by 
ARDS severity (PF ratio) and treatment were not significantly different (p=0.12).  Survival curves 
stratified by APACHE II score (dichotomized at the mean) and treatment revealed no differential 
effect of treatment in either the high or low APACHE groups (Figure S1).  
 
Mortality at 28 days was 32% (27/84) in the hyper-inflammatory subphenotype patients treated 
with simvastatin, in comparison to 45% (46/102) in the hyper-inflammatory subphenotype 
patients treated with placebo; in contrast, 28-day mortality was similar in patients in the hypo-
inflammatory subphenotype regardless of treatment assignment (16% (29/178) vs 17% 
(30/175)).  Analysis of interaction between treatment and subphenotype for mortality was not 
statistically significant (p=0.14).  
 
In the original trial, time to unassisted breathing did not differ significantly between simvastatin 
and placebo patients.  When stratified by subphenotype and treatment, time to unassisted 
breathing differed significantly (Figure 3; p < 0.0001).  However, the difference in the curves 
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between the hyper-inflammatory subphenotype patients treated with simvastatin and placebo 
was not statistically significant (p=0.10).  In the hyper-inflammatory subphenotype, median 
ventilator-free days (VFD) were numerically higher in the simvastatin-treated patients compared 
to placebo (7 VFD vs 0 VFD), in contrast to patients in the hypo-inflammatory subphenotype 
where the median number of ventilator-free days was the same regardless of treatment (18 VFD 
in each); however, the interaction between treatment and subphenotype in regression models 
was not statistically significant (p=0.15).    
 
DISCUSSION 
      These analyses have two novel findings with important implications for future clinical trials in 
ARDS.  First, two distinct ARDS subphenotypes with features similar to those we have 
previously reported were identified for the first time in a non-United States patient population 
and using a different and much smaller set of clinical and biomarker data than in previous 
studies.  These findings indicate that these subphenotypes are consistent across geographic 
sites and are robust to variations in specific data collected, enhancing the generalizability of 
previous studies.  Second, and more importantly, these two subphenotypes of ARDS responded 
differently to randomly assigned simvastatin, with evidence of improved survival at both 28 and 
90 days uniquely among patients with a “hyper-inflammatory” subphenotype of ARDS.  These 
findings suggest that identification of ARDS subphenotypes may be fundamentally important in 
future ARDS clinical trials and, more broadly, that targeting distinct subphenotypes of critical 
illness syndromes may finally yield progress after decades of negative pharmacotherapy trials in 
the ICU.   
 The heterogeneous, clinically defined syndromes of sepsis and ARDS are thought of as 
“graveyards” for novel pharmacotherapies, despite their high prevalence and mortality, and yet 
critical care has lagged behind other fields in its development of precision biomarker-guided 
treatments.15  The concept of targeting specific biomarker-defined subgroups of heterogeneous 
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syndromes, a variant of precision medicine, has fundamentally changed the approach to patient 
care in oncology, with examples ranging from estrogen receptor status in breast cancer to 
BRAF mutation status in melanoma and other malignancies.16  In other fields, such as asthma, 
recognition of the importance of distinct subphenotypes is critical to the design of new clinical 
trials and is beginning to impact patient care.17  Over the past several years, there has been 
increasing evidence of the biological and clinical heterogeneity in sepsis and ARDS, including 
our prior work showing subphenotype-specific responses to PEEP and fluid management 
strategy, but until now, there has not been evidence that biologically distinct subphenotypes 
have differential response to pharmacotherapy in ARDS.  
 The finding that patients with a hyper-inflammatory ARDS subphenotype preferentially 
responded to randomly assigned simvastatin has biologic plausibility based on the presumed 
mechanism of action of statins in ARDS.  Statins reduce lung inflammation and injury in both 
animal models of ARDS and pre-clinical human experimental studies9 and have endothelial-
stabilizing properties as well.  Thus, patients with a higher degree of systemic inflammation such 
as those in the hyper-inflammatory subphenotype would seem to be most likely to respond to 
this therapy.   
 In this analysis as in our prior studies on the same topic, we note that extra-pulmonary 
factors (such as creatinine, bilirubin, and platelet levels) seemed to contribute more to 
subphenotype identification than pulmonary-specific variables such as P/F ratio and ventilator 
parameters.  One potential explanation for these findings is that patients were enrolled into this 
trial (as all ARDS clinical trials) on the basis of specific pulmonary criteria (e.g. PF ratio), while 
other pulmonary criteria (e.g. tidal volume, plateau pressure) are determined at least in part by 
protocols designed for ARDS patients.  Thus, it is not entirely surprising that these pulmonary 
criteria converge and therefore contribute less to identifying subgroups of patients than non-
pulmonary criteria.  At the same time, it is also possible that the biological differences between 
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subphenotypes either drive or are driven by multi-system organ failure, which then contributes 
to poorer outcomes.     
 We observed a clinically significant but not statistically significant difference in VFDs for 
patients in the hyper-inflammatory subphenotype treated with simvastatin (median 7 VFDs) vs 
placebo (median 0 VFDs).  These data stand in contrast to the findings of the survival analysis 
(Figure 2), in which survival was significantly better with simvastatin in the hyper-inflammatory 
subphenotype.  Our interpretation of these results is that the VFD analyses may be 
underpowered and likely reflect a pattern of preferential benefit to simvastatin in the hyper-
inflammary subphenotype similar to that identified in survival analysis, though other 
interpretations are also possible.  Nevertheless, these findings highlight some of the challenges 
in using VFDs as an outcome for clinical trials in ARDS.    
When considering the results of any subgroup analysis in a clinical trial, several 
important issues (in addition to biologic plausibility) must be considered, including multiple 
hypothesis testing, “post hoc” analyses, and statistical power and methodology.18 In the present 
analysis, only one subgroup analysis was pursued:  specifically, latent classes were sought 
using an unbiased, data-driven approach that has identified distinct ARDS subphenotypes in 3 
prior studies.  Thus, multiple hypothesis testing (aside from the hypothesis of the original clinical 
trial) should not be an issue.  This analysis was not planned as part of the original trial design 
because the trial was designed before our group’s first description of ARDS subphenotypes.19  
However, given our previous findings that ARDS subphenotypes responded differently to 
randomly assigned interventions (PEEP, fluid conservative therapy) in 2 prior large clinical trials, 
we thought it was an important hypothesis to test in this analysis.  As with many subgroup 
analyses, the original HARP2 trial was not powered for this analysis; we also note that despite a 
13% absolute risk reduction for mortality in the hyper-inflammatory subphenotype with 
simvastatin vs. placebo, the statistical test for interaction in the analyses of 28-day mortality was 
not statistically significant (p=0.14).  In this case, given the biologic plausibility of a preferential 
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response to statins in the hyper-inflammatory subphenotype, as well as our prior findings of 
differential treatment responses to other interventions, we thought it was appropriate to directly 
compare the survival curves for hyper-inflammatory patients treated with simvastatin vs. 
placebo.  A prospective clinical trial of simvastatin targeting hyper-inflammatory ARDS patients, 
however, must be conducted prior to making any treatment recommendations for this group.   
 This study has several strengths, including the consistency of the LCA results compared 
to prior studies, the data-driven and unbiased nature of LCA for subgroup identification, the 
biologic plausibility of the results, and the setting within a randomized controlled trial, which 
allows stronger causal inference regarding treatment effects, as compared with observational 
studies.   This study also has some limitations, most of which derive from its origin as a 
subgroup analysis and are detailed above.  As in some other prior ARDS clinical trials,20,21 
plateau pressure was missing in a substantial proportion of patients (45%).  While latent class 
models can include patients with missing data, more complete data on this variable may have 
been helpful.  In addition, because of the nature of latent class models, we note that it is not 
possible to prove that the two subphenotypes identified in this cohort are “the same” as the two 
subphenotypes identified in our prior studies, although the similarity of the clinical and biological 
variables distinguishing the two groups in this work and prior studies provides strong evidence 
in support of this hypothesis.  As in nearly all randomized controlled trials in ARDS, mortality 
was lower in the HARP2 cohort than in contemporary observational ARDS cohorts;2 additional 
studies of ARDS subphenotypes in less carefully selected patient populations are needed.  
Finally, we wish to emphasize again that patients in the original trial were not randomized on the 
basis of their ARDS subphenotype, so in addition to the aforementioned caveats regarding 
subgroup analyses, it remains possible that unmeasured confounders could be contributing to 
our findings.  Prospective confirmation of simvastatin benefit in the hyper-inflammatory 
subphenotype in a randomized controlled trial will be necessary.   
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Moving forward, how might these findings be translated to future clinical trials in ARDS?  
As reported in prior studies, the hyper-inflammatory ARDS subphenotype can be accurately 
identified using as few as 3 variables (e.g. IL-8, sTNFr1, bicarbonate).5,6  The development of 
the capability to measure these biomarkers in real time will be critical to conducting precision 
clinical trials in this setting.  More broadly, these results suggest that predictive enrichment 
approaches to critical care clinical trials should be strongly considered.  Investigators studying 
sepsis have identified distinct subtypes within that heterogeneous syndrome, defined by 
differences in whole blood gene expression, though testing for differential responses to 
randomly assigned treatment has not yet been carried out.22,23  If similar patterns are identified 
in sepsis, it would suggest that clinical trials in syndromes known to encompass significant 
biological heterogeneity should consider targeting patients based on their underlying biology 
rather than on a less specific syndromic diagnosis.   
In conclusion, this secondary analysis of the HARP-2 trial of simvastatin for ARDS 
identifies two distinct subphenotypes of ARDS, one of which had significantly improved survival 
with simvastatin therapy compared to placebo.  Two distinct subphenotypes of ARDS have now 
been identified in four different randomized controlled trial cohorts, with differential responses to 
mechanical ventilation, fluid management strategy, and now pharmacotherapy.  These findings 
support further pursuit of predictive enrichment strategies in critical care clinical trials.    
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Figure Legends 
 
Figure 1:  Continuous Variables By Subphenotype. Differences in standardized values of each 
continuous variable by subphenotype in the HARP-2 Study. The variables are sorted on the 
basis of the degree of separation between the subphenotypes, from maximum positive 
separation on the left (ie, hyper-inflammatory subphenotype higher than hypo-inflammatory 
subphenotype) to maximum negative separation on the right (ie, hyper-inflammatory 
subphenotype lower than hypo-inflammatory subphenotype). The y-axis represents 
standardized variable values, in which all means are scaled to zero and SDs to one. A value of 
+1 for the standardized variable signifies that the mean value for a given subphenotype was one 
SD higher than the mean value in the cohort as a whole. Mean values are joined by lines to 
facilitate displaying subphenotype profiles.  sTNFr1= soluble tumor necrosis factor receptor-1.  
IL-6 = interleukin-6. 
 
Figure 2:  Kaplan-Meier survival curves to 28 days (Figure 3A) and 90 days (Figure 3B) for 
patients in HARP-2, stratified by ARDS subphenotype and treatment (simvastatin vs placebo).  
Comparison of curves using the log-rank test.  Figure 3A:  overall p<0.0001; comparison of 
hyper-inflammatory subphenotype patients treated with simvastatin vs placebo p= 0.008.  
Figure 3B:  overall p<0.0001; comparison of hyper-inflammatory subphenotype patients treated 
with simvastatin vs placebo p=0.03. 
 
Figure 3:  Time to unassisted breathing over 28 days, stratified by subphenotype and treatment 
condition, from Fine-Gray competing risks model.  Overall p<0.0001; comparison of hyper-
inflammatory subphenotype patients treated with simvastatin vs. placebo p=0.10. 
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Table 1:   Values of Key Subphenotype-Defining Variables At Baseline, Stratified by 
Subphenotype 
 
Baseline Characteristic Hypo-inflammatory 
Subphenotype 
(n=353) 
Hyper-inflammatory 
Subphenotype 
(n=186) 
P-Value 
Age 51 ± 16 60 ± 15 <.0001 
Female gender, n (%) 157 (45) 75 (40) .32 
Direct ARDS Risk Factors, 
n (%) 
  <.0001 
     Aspiration 36 (10) 13 (7)  
     Pneumonia 214 (61) 81 (43)  
     Trauma 26 (7) 5 (3)  
     Other 24 (7) 4 (2)  
     None 52 (15) 84 (45)  
Indirect ARDS Risk Factors, 
n (%) 
  <.0001 
     Sepsis 116 (33) 108 (58)  
     Pancreatitis 4 (1) 14 (7)  
     Other 19 (5) 14 (7)  
     None 213 (61) 51 (27)  
Vasopressor Use, n (%) 205 (58) 151 (81) <.0001 
P/F Ratio, kPa 17.6 ± 8 16.1 ± 7 .02 
Plateau pressure, cm H20 24 ± 6 24 ± 6 .87 
Tidal volume, ml/kg 8.3 ± 2.6 7.9 ± 2.6 .099 
Platelet count, thousands 216 ± 119 148 ± 114 <.0001 
Bilirubin, umol/L, median 
(IQR) 
9 (6-16) 19.5 (11-36) <.0001 
Creatinine, umol/L 76 ± 42 156 ± 91 <.0001 
C-reactive protein, mg/L 174 ± 109 208 ± 110 .0008 
IL-6, pg/ml, median (IQR) 79 (35-197) 348 (133-1355) <.0001 
sTNFr1, pg/ml, median 
(IQR) 
3511 (2382-5008) 11202 (7810-16703) <.0001 
Randomized to simvastatin, 
n (%) 
174 (49) 85 (45) .38 
 
Values represent mean ± standard deviation, unless otherwise specified. 
Abbreviations:  IL-6 = interleukin 6.  sTNFr1 = soluble tumor necrosis factor receptor 1. 
Statistical comparison by Pearson’s chi-square, t-test, or Wilcoxon rank-sum as appropriate. 
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Table 2:  Clinical Outcomes By Subphenotype 
 
 
 Hypo-
inflammatory 
Subphenotype 
(n=353) 
Hyper-
inflammatory 
Subphenotype 
(n=186) 
p-value 
28 Day Mortality, n (%) 59 (17%) 73 (39%) <0.0001 
90 Day Mortality, n (%) 78 (22%) 87 (46%) <0.0001 
Ventilator-Free Days, median (25-
75%) 
18 (0-23) 2 (0-17) <0.0001 
Non-pulmonary organ failure-free 
days, median (25-75%) 
27 (21-28) 15 (0-25) <0.0001 
 
Ventilator-free days and non-pulmonary organ failure-free days measured to day 28. 
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ABSTRACT: 
Background:  Precision medicine approaches targeting patients based on disease subtype 
have transformed approaches to cancer, asthma, and other heterogeneous syndromes.  Two 
distinct subphenotypes of ARDS have been identified in three US-based clinical trials and 
respond differently to positive end-expiratory pressure and fluid management.  It remains 
unknown if these subphenotypes exist in different populations and respond differently to 
pharmacotherapies. 
Methods:  We conducted a secondary analysis using data from 539 patients enrolled in a UK 
multicenter, placebo-controlled randomized trial of simvastatin for ARDS (HARP-2).  Latent 
class analysis was applied to baseline data without consideration of outcomes to identify 
subphenotypes.  Clinical outcomes were compared across subphenotypes and treatment 
groups.  
Findings:  A two class (two-subphenotype) model was an improvement over a one class model 
(p<0.0001), with 65% of subjects in the hypo-inflammatory subphenotype and 35% in the hyper-
inflammatory subphenotype.  Additional classes did not improve model fit.  The clinical and 
biological characteristics of the two subphenotypes were similar to prior studies.  While the 
original trial found no difference in 28-day survival between placebo and simvastatin, 
significantly different survival was identified across patients stratified by treatment and 
subphenotype (p<0.0001).  Specifically, within the hyper-inflammatory subphenotype, patients 
treated with simvastatin had significantly higher 28-day survival compared to placebo (p = 
0.008).  A similar pattern was observed for 90-day survival. 
 3 
Interpretation:  Two subphenotypes of ARDS were identified in the HARP-2 cohort, with 
distinct clinical and biological features and disparate clinical outcomes; the hyper-inflammatory 
subphenotype had improved survival with simvastatin compared to placebo.  These findings 
support further pursuit of predictive enrichment strategies in critical care clinical trials. 
Word count:   257/250  
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RESEARCH IN CONTEXT 
Evidence before this study:  Previous studies of ARDS patients, using data from U.S.-based 
randomized controlled trials, have identified two distinct subphenotypes with differential 
responses to mechanical ventilation and fluid therapy.  It is unknown whether these 
subphenotypes can be identified in different populations using different datasets and, more 
importantly, whether these subphenotypes respond differently to pharmacotherapies.  We 
searched PubMed on March 7, 2018 using the terms (ARDS or “acute lung injury”) AND 
(subtype OR subphenotype OR endotype) and no language restrictions and identified no prior 
studies reporting differential responses to pharmacotherapy by ARDS subphenotype. 
 
Added value of this study:  This study reports that two distinct ARDS subphenotypes were 
identified in a secondary analysis of a U.K.-based randomized controlled trial of simvastatin for 
ARDS.  Notably, the hyper-inflammatory subphenotype of ARDS had a survival benefit from 
simvastatin.  To our knowledge, this study is the first to report differential response to 
pharmacotherapy by molecular subphenotype in ARDS. 
 
Implications of all the available evidence:  While other areas of medicine (e.g. cancer, 
asthma) have made significant progress by identifying biologically distinct subtypes of disease 
with differential treatment responses, critical care medicine has lagged behind.  These findings 
suggest that targeting specific biological subtypes of critical illness syndromes in clinical trials 
may yield progress after decades of negative pharmacotherapy trials in the ICU. 
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INTRODUCTION 
 The acute respiratory distress syndrome (ARDS) is a common and frequently fatal cause 
of respiratory failure among critically ill patients, with an incidence of nearly 200,000 cases per 
year in the US alone, an estimated prevalence of 10% among critically ill patients worldwide, 
and mortality of 30-40%.1,2 ARDS is defined by clinical criteria including acute onset of 
hypoxemia (PaO2/FiO2 ratio < 300 mm Hg), bilateral chest radiographic opacities, and 
exclusion of cardiac failure as the sole cause of the syndrome.3  Since the first consensus 
definition of ARDS in 1988, experts have debated whether patients should be subdivided by 
natural history, clinical features, biology, or some combination thereof.4  During the ensuing 3 
decades, positive trials of several supportive care interventions, including most notably lung 
protective ventilation, have led to decreases in ARDS mortality – yet over the same time period, 
dozens of pharmacotherapies that seemed to show great promise in pre-clinical studies have 
failed in clinical trials.  One of the often-cited reasons for this discouraging failure rate has been 
the considerable clinical and biological heterogeneity within ARDS, but objective data have 
been lacking to guide a more precision approach to clinical trials. 
 Latent class analysis is a well-validated statistical method that uses objective criteria to 
identify subgroups within a broader population.  We previously applied latent class analysis in 
independent analyses of 3 cohorts of patients derived from NHLBI ARDS Network randomized 
controlled trials; in all 3 cohorts, summing to over 2000 patients, we observed strong evidence 
for two distinct and consistent subphenotypes of ARDS.5,6  In all 3 cohorts, one subphenotype 
representing roughly 30% of ARDS patients was consistently characterized by higher levels of 
inflammatory biomarkers, more profound shock and acidosis, and significantly worse clinical 
outcomes.  Of particular interest, we found that this hyper-inflammatory subphenotype had a 
significantly different response to randomly assigned positive end-expiratory pressure (PEEP) 
and fluid management strategy, compared to the hypo-inflammatory subphenotype.5,6  These 
findings have suggested that improved understanding of these subphenotypes may be critical to 
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future success in ARDS clinical trials.7  It remains unknown, however, whether these ARDS 
subphenotypes are generalizable to non-U.S. populations, whether they can be identified using 
less extensive datasets, and most importantly, whether they may respond differently to 
pharmacotherapies.   
 To test these questions, we designed a secondary analysis of a Phase 2B randomized 
controlled trial of simvastatin for ARDS, the Hydroxymethylglutaryl-CoA Reductase Inhibition 
with Simvastatin in Acute Lung Injury to Reduce Pulmonary Dysfunction-2 (HARP-2) Study.8  
Based on our prior research, we hypothesized a priori that latent class analysis of the HARP-2 
cohort would identify two distinct subphenotypes of ARDS with similar clinical and biological 
characteristics to those we have previously identified.  We also hypothesized, based on the anti-
inflammatory effects of statins in laboratory and pre-clinical models of ARDS,9 that patients with 
the hyper-inflammatory subphenotype would preferentially respond to simvastatin.   
 
METHODS 
Patient Sample 
HARP-2 was a multicenter randomized controlled trial conducted in the United Kingdom and 
Ireland comparing daily simvastatin 80 mg to placebo in 540 patients with ARDS.8  One patient 
withdrew consent for the use of their data, so 539 patients were analyzed.  Patients were 
enrolled within 48 hours of meeting ARDS criteria, and study drug was continued until Day 28, 
discharge from ICU, death, or development of a contraindication to continued statin therapy. 
The primary outcome of the study was ventilator-free days, with secondary outcomes of non-
pulmonary organ failure free days and mortality; there were no significant differences in any of 
these outcomes by treatment allocation.  
 
Assay Procedures 
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Interleukin 6 (IL-6) and soluble tumor necrosis factor receptor-1 (sTNFr-1) were measured for 
this analysis using plasma drawn prior to randomization and stored at -80C. Biomarkers were 
measured in duplicate using commercially available enzyme-linked immunoassays (R&D 
Systems).  
 
Statistical Analysis 
To estimate the optimal number of classes in the data, latent class models were fit in Mplus v810 
using baseline demographics (age, gender), available baseline clinical data (direct and indirect 
ARDS risk factors, bilirubin, creatinine, platelet count, PaO2/FiO2 ratio, plateau pressure, tidal 
volume, use of vasopressors), and baseline IL-6 and sTNFr1 as class-defining variables 
(Supplemental Table 1).  Of note, fewer clinical and biomarker variables were available for 
these analyses than in our prior studies. Outcome variables were not included in the modeling.  
Models ranging from 1 to 4 classes were estimated to identify the optimal number of classes. 
From these four models, best-fit was evaluated using Bayesian Information Criteria (BIC), the 
Vuong-Lo-Mendell-Rubin likelihood ratio (VLMR) test (which compares fit of model k classes to 
k-1 classes), class size, and entropy.11,12  Prior to beginning this modeling, variables were 
examined for their distribution, and continuous variables with significantly skewed distributions 
were log-transformed.  To estimate model parameters, continuous variables were placed on a z-
scale with a mean of 0 and standard deviation of 1, as in our prior work.5,6 As a sensitivity 
analysis, we repeated these models including C-reactive protein (CRP) levels.  Additional 
details on the LCA modeling are in the supplementary appendix.  
 
Once the optimal number of classes was determined, study participants were assigned to their 
most likely class, and their baseline characteristics were compared using t-tests, Pearson’s chi-
square, or Wilcoxon rank sum test depending on the nature of the variable. Associations 
between class assignment and clinical outcomes (28-day and 90-day mortality; ventilator-free 
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days) were tested using logistic regressionchi-square for mortality (i.e., the proportion who died) 
and zero-inflated Poisson regressionWilcoxon ranksum for ventilator-free days.  To test for 
interactions between treatment and class assignment, we used logistic regression for mortality 
and zero-inflated Poisson regression for ventilator-free days.  Count-based models of ventilator-
free-days were compared for best fit and tested for over-dispersion to inform model selection. 
Model diagnostics were satisfactory; details regarding model checking procedures are provided 
in the supplement.  To test for differential response to treatment by class for survival (time to 
death), we compared time-to-event Kaplan-Meier curves using the log-rank test. For modeling 
time to unassisted breathing, a competing risks model was estimated with death before Day 28 
as the competing risk.13  Analyses other than LCA were carried out using SAS (Version 9.4, 
(SAS Institute, Cary, NC, USA).  Some results were previously reported in the form of an 
abstract.14 
 
Role of the Funding Source:  None 
 
Results  
Population Characteristics 
Baseline characteristics of patients enrolled in the HARP-2 trial are fully described in the 
original publication and are summarized in Supplemental Table 2.  Pneumonia was the most 
common contributing risk factor for ARDS (55%). Overall, median ventilator-free days were 13, 
and 28-day mortality was 24.5%.  
 
Two-class Model Optimally Fits the Population 
Analysis of the four LCA models showed that the 2-class model was a better fit for the 
population than a 1-class model, and additional classes did not improve model fit 
(Supplementary Table 3). Entropy in all models was 0.75 or greater, indicating adequate class 
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separation. The Bayesian Information Criteria decreased as the number of classes in the model 
increased, indicating improved model fit with additional classes. The 2-class model had a 
significantly improved fit compared to the one-class model (VLMR p < 0.0001); additional 
classes did not lead to significant improvement in model fit.  These findings, in conjunction with 
the relatively small number of patients in the additional class in a 3-class model (n = 40), led us 
to proceed using a 2-class model.  In the 2-class model, 353 (65%) patients were assigned to 
class 1 and 186 (35%) patients to class 2.  Of note, these proportions are consistent with our 
prior latent class analyses,5,6 despite the fact that the HARP-2 analyses used far fewer clinical 
and biomarker variables (n=14) as inputs than the prior work (n=35-37).  Inclusion of CRP levels 
in the LCA models as a sensitivity analysis did not meaningfully affect the results (data not 
shown). 
Average latent class probabilities were 0.93 for Class 1 and 0.92 for Class 2. These 
findings are also consistent with previous studies and indicative of robust class assignment.   
 
Comparison of Phenotypic Features and Outcomes Between Subphenotypes 
Class 2 had clinical and biological features similar to those found in prior studies and 
consistent with a hyper-inflammatory phenotype.  Specifically, as compared to Class 1, patients 
in Class 2 had higher values of sTNFr-1 and IL-6, lower platelet counts (Figure 1; Table 1), and 
more vasopressor use (Table 1; p < 0.001).   For simplicity, the classes will be referred to as the 
hypo-inflammatory subphenotype (Class 1) and the hyper-inflammatory subphenotype (Class 2) 
for the remainder of the manuscript.  Age and gender were similar across the subphenotypes.  
Although the distribution of direct and indirect ARDS risk factors was significantly different 
across the two subphenotypes (Table 1; p<0.0001), the most common ARDS risk factors of 
sepsis, pneumonia and aspiration were highly prevalent among both groups, as in prior studies. 
Also similar to prior studies, the hyper-inflammatory subphenotype patients had fewer ventilator-
free days (median 2 vs 18 days; p<0.0001), fewer non-pulmonary organ failure free days 
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(median 15 vs 27 days; p<0.0001), and higher 28-day mortality (39% vs 17%, p<0.0001) 
compared to the hypo-inflammatory subphenotype (Table 2).  
 
Survival Benefit Observed with Simvastatin in Hyper-inflammatory Subphenotype 
The original trial found no difference in 28-day survival curves between placebo and simvastatin 
(p=0.20).  In contrast, we observed significantly different survival curves across patients 
stratified by treatment and subphenotype (Figure 2A; p<0.0001).  Specifically, within the hyper-
inflammatory subphenotype, patients treated with simvastatin had significantly higher 28-day 
survival compared to patients treated with placebo (p = 0.008). This effect was not observed in 
the hypo-inflammatory subphenotype patients.  A similar pattern was observed for 90-day 
survival (Figure 2B; p<0.0001 for overall comparison; p=0.03 for hyper-inflammatory 
subphenotype simvastatin vs placebo).    
 
In contrast to the curves stratified by subphenotype and treatment, survival curves stratified by 
ARDS severity (PF ratio) and treatment were not significantly different (p=0.12).  Survival curves 
stratified by APACHE II score (dichotomized at the mean) and treatment revealed no differential 
effect of treatment in either the high or low APACHE groups (Figure S1).  
 
Mortality at 28 days was 32% (27/84) in the hyper-inflammatory subphenotype patients treated 
with simvastatin, in comparison to 45% (46/102) in the hyper-inflammatory subphenotype 
patients treated with placebo; in contrast, 28-day mortality was similar in patients in the hypo-
inflammatory subphenotype regardless of treatment assignment (16% (29/178) vs 17% 
(30/175)).  Analysis of interaction between treatment and subphenotype for mortality was not 
statistically significant (p=0.14).  
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In the original trial, time to unassisted breathing did not differ significantly between simvastatin 
and placebo patients.  When stratified by subphenotype and treatment, time to unassisted 
breathing differed significantly (Figure 3; p < 0.0001).  However, the difference in the curves 
between the hyper-inflammatory subphenotype patients treated with simvastatin and placebo 
was not statistically significant (p=0.10).  In the hyper-inflammatory subphenotype, median 
ventilator-free days (VFD) were numerically higher in the simvastatin-treated patients compared 
to placebo (7 VFD vs 0 VFD), in contrast to patients in the hypo-inflammatory subphenotype 
where the median number of ventilator-free days was the same regardless of treatment (18 VFD 
in each); however, the interaction between treatment and subphenotype in regression models 
was not statistically significant (p=0.15).    
 
DISCUSSION 
      These analyses have two novel findings with important implications for future clinical trials in 
ARDS.  First, two distinct ARDS subphenotypes with features similar to those we have 
previously reported were identified for the first time in a non-United States patient population 
and using a different and much smaller set of clinical and biomarker data than in previous 
studies.  These findings indicate that these subphenotypes are consistent across geographic 
sites and are robust to variations in specific data collected, enhancing the generalizability of 
previous studies.  Second, and more importantly, these two subphenotypes of ARDS responded 
differently to randomly assigned simvastatin, with evidence of improved survival at both 28 and 
90 days uniquely among patients with a “hyper-inflammatory” subphenotype of ARDS.  These 
findings suggest that identification of ARDS subphenotypes may be fundamentally important in 
future ARDS clinical trials and, more broadly, that targeting distinct subphenotypes of critical 
illness syndromes may finally yield progress after decades of negative pharmacotherapy trials in 
the ICU.   
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 The heterogeneous, clinically defined syndromes of sepsis and ARDS are thought of as 
“graveyards” for novel pharmacotherapies, despite their high prevalence and mortality, and yet 
critical care has lagged behind other fields in its development of precision biomarker-guided 
treatments.15  The concept of targeting specific biomarker-defined subgroups of heterogeneous 
syndromes, a variant of precision medicine, has fundamentally changed the approach to patient 
care in oncology, with examples ranging from estrogen receptor status in breast cancer to 
BRAF mutation status in melanoma and other malignancies.16  In other fields, such as asthma, 
recognition of the importance of distinct subphenotypes is critical to the design of new clinical 
trials and is beginning to impact patient care.17  Over the past several years, there has been 
increasing evidence of the biological and clinical heterogeneity in sepsis and ARDS, including 
our prior work showing subphenotype-specific responses to PEEP and fluid management 
strategy, but until now, there has not been evidence that biologically distinct subphenotypes 
have differential response to pharmacotherapy in ARDS.  
 The finding that patients with a hyper-inflammatory ARDS subphenotype preferentially 
responded to randomly assigned simvastatin has biologic plausibility based on the presumed 
mechanism of action of statins in ARDS.  Statins reduce lung inflammation and injury in both 
animal models of ARDS and pre-clinical human experimental studies9 and have endothelial-
stabilizing properties as well.  Thus, patients with a higher degree of systemic inflammation such 
as those in the hyper-inflammatory subphenotype would seem to be most likely to respond to 
this therapy.   
 In this analysis as in our prior studies on the same topic, we note that extra-pulmonary 
factors (such as creatinine, bilirubin, and platelet levels) seemed to contribute more to 
subphenotype identification than pulmonary-specific variables such as P/F ratio and ventilator 
parameters.  One potential explanation for these findings is that patients were enrolled into this 
trial (as all ARDS clinical trials) on the basis of specific pulmonary criteria (e.g. PF ratio), while 
other pulmonary criteria (e.g. tidal volume, plateau pressure) are determined at least in part by 
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protocols designed for ARDS patients.  Thus, it is not entirely surprising that these pulmonary 
criteria converge and therefore contribute less to identifying subgroups of patients than non-
pulmonary criteria.  At the same time, it is also possible that the biological differences between 
subphenotypes either drive or are driven by multi-system organ failure, which then contributes 
to poorer outcomes.     
 We observed a clinically significant but not statistically significant difference in VFDs for 
patients in the hyper-inflammatory subphenotype treated with simvastatin (median 7 VFDs) vs 
placebo (median 0 VFDs).  These data stand in contrast to the findings of the survival analysis 
(Figure 2), in which survival was significantly better with simvastatin in the hyper-inflammatory 
subphenotype.  Our interpretation of these results is that the VFD analyses may be 
underpowered and likely reflect a pattern of preferential benefit to simvastatin in the hyper-
inflammary subphenotype similar to that identified in survival analysis, though other 
interpretations are also possible.  Nevertheless, these findings highlight some of the challenges 
in using VFDs as an outcome for clinical trials in ARDS.    
When considering the results of any subgroup analysis in a clinical trial, several 
important issues (in addition to biologic plausibility) must be considered, including multiple 
hypothesis testing, “post hoc” analyses, and statistical power and methodology.18 In the present 
analysis, only one subgroup analysis was pursued:  specifically, latent classes were sought 
using an unbiased, data-driven approach that has identified distinct ARDS subphenotypes in 3 
prior studies.  Thus, multiple hypothesis testing (aside from the hypothesis of the original clinical 
trial) should not be an issue.  This analysis was not planned as part of the original trial design 
because the trial was designed before our group’s first description of ARDS subphenotypes.19  
However, given our previous findings that ARDS subphenotypes responded differently to 
randomly assigned interventions (PEEP, fluid conservative therapy) in 2 prior large clinical trials, 
we thought it was an important hypothesis to test in this analysis.  As with many subgroup 
analyses, the original HARP2 trial was not powered for this analysis; we also note that despite a 
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13% absolute risk reduction for mortality in the hyper-inflammatory subphenotype with 
simvastatin vs. placebo, the statistical test for interaction in the analyses of 28-day mortality was 
not statistically significant (p=0.14).  In this case, given the biologic plausibility of a preferential 
response to statins in the hyper-inflammatory subphenotype, as well as our prior findings of 
differential treatment responses to other interventions, we thought it was appropriate to directly 
compare the survival curves for hyper-inflammatory patients treated with simvastatin vs. 
placebo.  A prospective clinical trial of simvastatin targeting hyper-inflammatory ARDS patients, 
however, must be conducted prior to making any treatment recommendations for this group.   
 This study has several strengths, including the consistency of the LCA results compared 
to prior studies, the data-driven and unbiased nature of LCA for subgroup identification, the 
biologic plausibility of the results, and the setting within a randomized controlled trial, which 
allows stronger causal inference regarding treatment effects, as compared with observational 
studies.   This study also has some limitations, most of which derive from its origin as a 
subgroup analysis and are detailed above.  As in some other prior ARDS clinical trials,20,21 
plateau pressure was missing in a substantial proportion of patients (45%).  While latent class 
models can include patients with missing data, more complete data on this variable may have 
been helpful.  In addition, because of the nature of latent class models, we note that it is not 
possible to prove that the two subphenotypes identified in this cohort are “the same” as the two 
subphenotypes identified in our prior studies, although the similarity of the clinical and biological 
variables distinguishing the two groups in this work and prior studies provides strong evidence 
in support of this hypothesis.  AFinally, as in nearly all randomized controlled trials in ARDS, 
mortality was lower in the HARP2 cohort than in contemporary observational ARDS cohorts;2 
additional studies of ARDS subphenotypes in less carefully selected patient populations are 
needed.  Finally, we wish to emphasize again that patients in the original trial were not 
randomized on the basis of their ARDS subphenotype, so in addition to the aforementioned 
caveats regarding subgroup analyses, it remains possible that unmeasured confounders could 
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be contributing to our findings.  Prospective confirmation of simvastatin benefit in the hyper-
inflammatory subphenotype in a randomized controlled trial will be necessary.   
Moving forward, how might these findings be translated to future clinical trials in ARDS?  
As reported in prior studies, the hyper-inflammatory ARDS subphenotype can be accurately 
identified using as few as 3 variables (e.g. IL-8, sTNFr1, bicarbonate).5,6  The development of 
the capability to measure these biomarkers in real time will be critical to conducting precision 
clinical trials in this setting.  More broadly, these results suggest that predictive enrichment 
approaches to critical care clinical trials should be strongly considered.  Investigators studying 
sepsis have identified distinct subtypes within that heterogeneous syndrome, defined by 
differences in whole blood gene expression, though testing for differential responses to 
randomly assigned treatment has not yet been carried out.22,23  If similar patterns are identified 
in sepsis, it would suggest that clinical trials in syndromes known to encompass significant 
biological heterogeneity should consider targeting patients based on their underlying biology 
rather than on a less specific syndromic diagnosis.   
In conclusion, this secondary analysis of the HARP-2 trial of simvastatin for ARDS 
identifies two distinct subphenotypes of ARDS, one of which had significantly improved survival 
with simvastatin therapy compared to placebo.  Two distinct subphenotypes of ARDS have now 
been identified in four different randomized controlled trial cohorts, with differential responses to 
mechanical ventilation, fluid management strategy, and now pharmacotherapy.  These findings 
support further pursuit of predictive enrichment strategies in critical care clinical trials.    
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Figure Legends 
 
Figure 1:  Continuous Variables By Subphenotype. Differences in standardized values of each 
continuous variable by subphenotype in the HARP-2 Study. The variables are sorted on the 
basis of the degree of separation between the subphenotypes, from maximum positive 
separation on the left (ie, hyper-inflammatory subphenotype higher than hypo-inflammatory 
subphenotype) to maximum negative separation on the right (ie, hyper-inflammatory 
subphenotype lower than hypo-inflammatory subphenotype). The y-axis represents 
standardized variable values, in which all means are scaled to zero and SDs to one. A value of 
+1 for the standardized variable signifies that the mean value for a given subphenotype was one 
SD higher than the mean value in the cohort as a whole. Mean values are joined by lines to 
facilitate displaying subphenotype profiles.  sTNFr1= soluble tumor necrosis factor receptor-1.  
IL-6 = interleukin-6. 
 
Figure 2:  Kaplan-Meier survival curves to 28 days (Figure 3A) and 90 days (Figure 3B) for 
patients in HARP-2, stratified by ARDS subphenotype and treatment (simvastatin vs placebo).  
Comparison of curves using the log-rank test.  Figure 3A:  overall p<0.0001; comparison of 
hyper-inflammatory subphenotype patients treated with simvastatin vs placebo p= 0.008.  
Figure 3B:  overall p<0.0001; comparison of hyper-inflammatory subphenotype patients treated 
with simvastatin vs placebo p=0.03. 
 
Figure 3:  Time to unassisted breathing over 28 days, stratified by subphenotype and treatment 
condition, from Fine-Gray competing risks model.  Overall p<0.0001; comparison of hyper-
inflammatory subphenotype patients treated with simvastatin vs. placebo p=0.10. 
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Table 1:   Values of Key Subphenotype-Defining Variables At Baseline, Stratified by 
Subphenotype 
 
Baseline Characteristic Hypo-inflammatory 
Subphenotype 
(n=353) 
Hyper-inflammatory 
Subphenotype 
(n=186) 
P-Value 
Age 51 ± 16 60 ± 15 <.0001 
GenderFemale gender, n 
(%) 
157 (45) 75 (40) .32 
Direct ARDS Risk Factors, 
n (%) 
  <.0001 
     Aspiration 36 (10) 13 (7)  
     Pneumonia 214 (61) 81 (43)  
     Trauma 26 (7) 5 (3)  
     Other 24 (7) 4 (2)  
     None 52 (15) 84 (45)  
Indirect ARDS Risk Factors, 
n (%) 
  <.0001 
     Sepsis 116 (33) 108 (58)  
     Pancreatitis 4 (1) 14 (7)  
     Other 19 (5) 14 (7)  
     None 213 (61) 51 (27)  
Vasopressor Use, n (%) 205 (58) 151 (81) <.0001 
P/F Ratio, kPa 17.6 ± 8 16.1 ± 7 .02 
Plateau pressure, cm H20 24 ± 6 24 ± 6 .87 
Tidal volume, ml/kg 8.3 ± 2.6 7.9 ± 2.6 .099 
Platelet count, thousands 216 ± 119 148 ± 114 <.0001 
Bilirubin, umol/L, median 
(IQR) 
9 (6-16) 19.5 (11-36) <.0001 
Creatinine, umol/L 76 ± 42 156 ± 91 <.0001 
C-reactive protein, mg/L 174 ± 109 208 ± 110 .0008 
IL-6, pg/ml, median (IQR) 79 (35-197) 348 (133-1355) <.0001 
sTNFr1, pg/ml, median 
(IQR) 
3511 (2382-5008) 11202 (7810-16703) <.0001 
Randomized to simvastatin, 
n (%) 
174 (49) 85 (45) .38 
 
Values represent mean ± standard deviation, unless otherwise specified. 
Abbreviations:  IL-6 = interleukin 6.  sTNFr1 = soluble tumor necrosis factor receptor 1. 
Statistical comparison by Pearson’s chi-square, t-test, or Wilcoxon rank-sum as appropriate. 
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Table 2:  Clinical Outcomes By Subphenotype 
 
 
 Hypo-
inflammatory 
Subphenotype 
(n=353) 
Hyper-
inflammatory 
Subphenotype 
(n=186) 
p-value 
28 Day Mortality, n (%) 59 (17%) 73 (39%) <0.0001 
90 Day Mortality, n (%) 78 (22%) 87 (46%) <0.0001 
Ventilator-Free Days, median (25-
75%) 
18 (0-23) 2 (0-17) <0.0001 
Non-pulmonary organ failure-free 
days, median (25-75%) 
27 (21-28) 15 (0-25) <0.0001 
 
Ventilator-free days and non-pulmonary organ failure-free days measured to day 28. 
 
 
